top of page
Logo KM Horizontal BONE.png
  • LinkedIn
  • Facebook
  • Instagram
  • Threads

Direct To Patient (DTP): The Discount Is the Headline. The Data Is the Business.

Updated: 20 hours ago

If you run a pharma brand, every story you are reading about direct-to-patient(DTP) right now is a story about price. LillyDirect undercuts the list. NovoCare ships Wegovy to your door. TrumpRx puts a government front door on the whole thing. The discount is real, and if it is the only thing you are watching, you are missing where the advantage actually lives.


Price is the thing a competitor matches tomorrow. What you build underneath the storefront is the thing that compounds: a first-party, full-journey view of your own patients. That is the part almost no one is talking about.


Not every brand — but for chronic, refill-driven therapies where access is broken, the door is open. And it's about to widen from the cash-pay few to the covered many.

Why the door is just opening now

DTP is not for every brand. It works when three things are true at once. The condition is chronic and self-recognized, so the patient feels it and seeks it. The product ships and refills, so the relationship recurs instead of ending at one transaction. And there is enough access friction to make a direct path worth it: poor coverage, prior-auth walls, step therapy. A well-covered, one-and-done acute therapy is a storefront with nothing to sell twice. A chronic therapy with a motivated patient and a broken access experience is a business.


GLP-1s happened to check every box, which is why they went first. Treat them as the proof of concept, not the whole market, because the model is already generalizing. Novartis put Cosentyx on a direct channel in late 2025. Bristol Myers Squibb launched Patient Connect. AstraZeneca and Amgen built their own [1]. Lilly is extending LillyDirect beyond obesity into migraine and diabetes [2]. The playbook is leaving the GLP-1 lane.


The scale is no longer experimental. LillyDirect launched in January 2024 and reached more than a million patients in its first full year [3]. NovoCare Pharmacy followed in March 2025 [4]. Hims & Hers now serves more than two million patients. After settling with Novo Nordisk in early 2026, it stopped selling compounded copies and became a distributor of branded medicine — a competitor turned channel [5]. TrumpRx.gov launched as a federal aggregator in February 2026 [3], and Medicare Part D began covering GLP-1s for weight management at a $50 monthly cap on July 1, 2026 [6]. Analysts put the pharma-and-telehealth convergence near $791 billion by 2032, a market too big to stay a GLP-1 story [7].


But here is the ceiling most brands have not priced in: cash-pay DTP is built for the coverage gap, not the covered patient. Novo Nordisk said it plainly — 90% of Wegovy patients with coverage already pay $0–$25 a month, so the direct channel exists for the other 10% [4]. Ask a covered patient to pay $499 in cash instead of a $25 copay and most walk away. A Rock Health study found 47% of people considering GLP-1s named cost as the top deterrent, and 36% of past users quit over cost [8]. A cash-pay-only strategy serves a minority by design, and it leaves you with a clear view of the few and no view of the many.


That ceiling is about to lift. Direct-to-employer and direct-to-payer capabilities are bringing the covered patient through the same door. Multi-pay models already run at Boehringer, Amgen, and BMS: insurance first, real-time benefits check, prior-auth and copay support built in, cash only as the fallback [1]. Employers are subsidizing manufacturer prices directly through programs like GoodRx Employer Direct [9] and Lilly's Employer Connect [10]. And the logical endpoint, still early, is the direct channel running through coverage rather than around it. The covered patient uses the same front door and the benefit still pays. Cash-pay was the proof of concept. Multi-pay is the mainstream.


he discount makes the headlines. The advantage is a first-party view of the whole journey, ad to refill, with no lag and nowhere for the leak to hide.

The unspoken value of DTP

Here is what the pricing coverage misses entirely. When you go direct, you stop renting fragments of the patient journey from media vendors, payers, and pharmacies, and start owning the whole record yourself.


Think about how the journey works today. A patient sees an ad, disappears for weeks, maybe books a visit, maybe gets a script, maybe clears prior auth, maybe fills, maybe refills. Every "maybe" is a handoff to a different party, and you receive a fragmented postcard from each one, weeks late, that never stitches back into a single person. You are measuring a journey you cannot actually see.


Picture one patient. She sees the ad, starts therapy, feels the early nausea, and quietly stops at her third refill. Today you learn that months later, in aggregate, if you learn it at all. In a direct model you see the wobble at refill two and can reach her before she is gone.


DTP collapses that relay into one owned track. For the first time, you can answer the question you have never been able to answer: where, exactly, is the bucket leaking? Which creative and channel started patients, not just generated clicks. How many qualified intakes stalled before a script. Where first-fill conversion drops. When adherence bends downward, for which kind of patient, early enough to act instead of eulogizing it a quarter later.


Two things change, and both matter. The insight is longitudinal and first-party — real people on therapy, observed directly, not a lookalike segment bought stale from a data vendor. And the lag collapses from quarters to near-real-time. You stop steering by the rear-view mirror and start steering by the windshield.


And as direct-to-employer and direct-to-payer bring covered patients through the same front door, that view stops covering only the self-pay slice and starts covering the whole book. The leaky-bucket visibility and the adherence advantage extend to the ninety percent, not just the ten. That is the moat. Price gets matched; an always-current view of your own patients only gets deeper with every cohort, while a fast follower starts from zero.


Faster diagnosis, quicker treatment, less friction, better adherence — all feeding one connected view. Capturing it is easy. Steering by it is the work.

Painting a picture of DTP tomorrow

Put it together and the future for the right brand is concrete. Faster time to diagnosis, because the digital front door meets intent in hours instead of weeks. Quicker time to treatment, because intake, script, and fulfillment sit on one rail. Less friction at the counter, because there is no counter and no prior-auth queue to abandon in. Better adherence, because you run refills, titration, and check-ins as a program instead of hoping the patient self-navigates.


Every one of those wins throws off the same by-product: data on the same patient, from first impression to nth refill, with no one in between filtering it. And soon that will be true for the covered patient and the cash-pay patient alike, which turns the advantage from affordability into reach.


Most brands will build the storefront and capture the data. Far fewer will build the reflexes to act on it with no lag... across media, HCP engagement, and refill. That, not the discount, is where the advantage is won. Seeing the whole journey and steering by it are two different capabilities, and the gap between them is the work.



The gap is where Kairos Meridian works. We don't build the pipes, and we have nothing to sell you — no platform, no media to mark up. The advice is the product. That independence is the point. A direct channel is not one vendor; it is a chain of them — your AOR, your media partners, your telehealth providers, your digital pharmacy, and the data layer beneath all of it. Each one optimizes its own slice. Someone has to sit across the whole chain, align it to one strategy and one set of metrics making the handoffs clean so the loop actually closes. That someone cannot be a vendor with a slice to protect.


If you are standing up a direct channel, or already have one and cannot yet turn what it shows you into decisions, let's talk. The first conversation is short, not a pitch — just the DTP opportunity keeping you up at night.



Sources

  1. IntuitionLabs, "Direct-to-Patient Pharma Platforms: DTC Disruption Models" (Novartis Cosentyx, BMS Patient Connect, AstraZeneca, Amgen, and Boehringer multi-pay). https://intuitionlabs.ai/articles/direct-to-patient-pharma-platforms-dtc-disruption

  2. Eli Lilly, "Lilly and U.S. government agree to expand access to obesity medicines" (Emgality, Trulicity, and Mounjaro added to LillyDirect self-pay). https://lilly.gcs-web.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines

  3. Journal of Medical Internet Research, "Affordable GLP-1? When Digital Platforms Meet Policy Reform" (LillyDirect 1M+ patients in 2025; TrumpRx.gov launch, February 5, 2026). https://www.jmir.org/2026/1/e102069

  4. Novo Nordisk, "Novo Nordisk introduces NovoCare Pharmacy" (March 5, 2025 launch; 90% of Wegovy patients pay $0–$25; $499/month cash price). https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html

  5. Telehealth Ally, "Hims & Hers 2026: after the Novo settlement" (2M+ patients; early-2026 pivot from compounded to branded distribution). https://www.telehealthally.com/guides/hims-hers-review-guide

  6. GivePayments, "GLP-1 Payment Processing in 2026" (Medicare Part D $50/month GLP-1 cap effective July 1, 2026). https://www.givepayments.com/blog/glp1-payment-processing-2026/

  7. DrugPatentWatch, "The Great Convergence: Pharmaceuticals, Digital Health, and the Direct-to-Patient Paradigm" ($791B market projection by 2032). https://www.drugpatentwatch.com/blog/the-great-convergence-pharmaceuticals-digital-health-and-the-direct-to-patient-paradigm/

  8. Life Science Leader, "Pharma Direct-To-Patient 2.0: From Experiment To Imperative" (Rock Health: 47% cite cost as top deterrent; 36% of past users stopped over cost). https://www.lifescienceleader.com/doc/pharma-direct-to-patient-from-experiment-to-imperative-0001

  9. GoodRx, "GoodRx Expands Into Employer Market With Launch of GoodRx Employer Direct" (February 24, 2026). https://investors.goodrx.com/news-releases/news-release-details/goodrx-expands-employer-market-launch-goodrx-employer-direct

  10. Healthcare Brew, "GoodRx, Eli Lilly launch direct-to-employer models that reduce reliance on PBMs" (Lilly Employer Connect, Zepbound KwikPen at $449). https://www.healthcare-brew.com/stories/2026/03/11/goodrx-eli-lilly-direct-to-employer-models-reduce-reliance-pbms

bottom of page